Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Net Income towards Common Stockholders (2020 - 2022)

Historic Net Income towards Common Stockholders for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$34.4 million.

  • Atea Pharmaceuticals' Net Income towards Common Stockholders fell 12939.5% to -$34.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$115.9 million, marking a year-over-year decrease of 19564.24%. This contributed to the annual value of -$168.4 million for FY2024, which is 2385.26% down from last year.
  • According to the latest figures from Q4 2022, Atea Pharmaceuticals' Net Income towards Common Stockholders is -$34.4 million, which was down 12939.5% from -$8.1 million recorded in Q3 2022.
  • Atea Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $117.1 million for Q4 2021, and its period low was -$42.1 million during Q1 2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$152545.5, with a median of -$10.0 million in 2020.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 46706.04% in 2021, then crashed by 213606.24% in 2022.
  • Atea Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $20.7 million in 2020, then surged by 467.06% to $117.1 million in 2021, then crashed by 129.4% to -$34.4 million in 2022.
  • Its Net Income towards Common Stockholders was -$34.4 million in Q4 2022, compared to -$8.1 million in Q3 2022 and -$31.3 million in Q2 2022.